Supplement

Carnosine

beta-alanyl-L-histidine

Evidence TierCWADA NOT PROHIBITED

tuneTypical Dose

2 g/day

watchEffect Window

Start with 2-12 weeks for most practical outcomes.

check_circleCompliance

WADA NOT PROHIBITED

Overview

Clinical Summary

Carnosine is a dipeptide with modest human evidence for glycemic support in prediabetes or type 2 diabetes and a narrower cognition signal in younger adults, but it is not a dependable performance supplement.

Oral carnosine is biologically interesting but pharmacokinetically limited because circulating carnosinase rapidly breaks it down. The best current human evidence is a small meta-analysis showing modest glycemic improvements in prediabetes and type 2 diabetes, plus a 2025 RCT showing age-dependent cognitive benefits in younger healthy adults. For exercise performance, beta-alanine remains the more evidence-based way to raise muscle carnosine.

Carnosine is a dipeptide with anti-glycation, antioxidant, and intracellular buffering activity, but oral use is limited by rapid degradation from serum carnosinase. Human benefits appear most plausible for glycemic endpoints in metabolically stressed populations rather than for direct ergogenic effects.

Outcomes

What This Is Expected To Influence

Primary Outcomes

  • Modest improvements in fasting glucose and HbA1c in prediabetes or type 2 diabetes
  • Possible age-dependent cognitive-speed benefit in younger healthy adults

Secondary Outcomes

  • Not a dependable ergogenic aid compared with beta-alanine
  • Safety is generally acceptable in short-term 1 to 2 g/day trials

Safety

Contraindications and Interactions

Contraindications

  • Pregnancy/lactation
  • Severe liver or kidney disease
  • Medication interactions

Side effects

  • GI discomfort
  • Drowsiness/sedation (agent-dependent)
  • Headache

Interactions

  • Drug absorption interactions
  • Sedatives/CNS-active agents
  • Anticoagulants

Avoid if

  • Unknown source quality
  • Unstable medical conditions
  • Complex medication stack

Evidence

Study-level References

carnosine-SRC-001Evidence scan (mixed trial quality)

PubMed evidence scan for "Carnosine" + "human trial".

Population: Adults in variable clinical and non-clinical settings

Dose protocol: Mixed historical carnosine protocols

Key findings: Legacy background scan describing mixed carnosine literature and broad uncertainty rather than a single definitive efficacy result.

Notes: Keep as background only. Primary modern claims should rest on the PubMed-backed 2025 meta-analysis and NEAT RCT.

Paper content

Mixed to weak, often context-specific

carnosine-SRC-003Systematic review and meta-analysis of randomized controlled trials.
Sourceopen_in_new

Li N, Yan X, Lin J, Wu M, et al. Effect of carnosine or beta-alanine supplementation therapy for prediabetes or type 2 diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials. BMC Endocr Disord. 2025;25(1):210. doi:10.1186/s12902-025-02016-w. PMID:40999397.

Population: Individuals with prediabetes or type 2 diabetes mellitus.

Dose protocol: Carnosine or beta-alanine vs placebo across 8 RCTs (377 participants)

Key findings: Significant reductions in fasting blood glucose (SMD -0.53) and HbA1c (SMD -0.36), improved beta-cell function.

Notes: Meta-analysis of 8 RCTs. Strongest pooled evidence for glycemic endpoints in prediabetes and T2DM.

Paper content

This systematic review and meta-analysis pooled data from 8 RCTs (377 participants) to evaluate the effects of carnosine or beta-alanine supplementation in people with prediabetes or type 2 diabetes. Supplementation significantly reduced fasting blood glucose and HbA1c, improved beta-cell function (HOMA-beta), and lowered total cholesterol compared to placebo. No significant effects were found for BMI, fasting insulin, or lipoprotein fractions. The findings support carnosine and beta-alanine as potential adjunct therapies for glycemic management in metabolically at-risk populations, though the included trials were small and heterogeneous in design.

carnosine-SRC-004Randomized, double-blind, placebo-controlled trial.
Sourceopen_in_new

O'Toole TE, Amraotkar AR, Gao H, Sears CG, Rai SN, Basner M, Bhatnagar A. Carnosine supplementation improves cognitive outcomes in younger participants of the NEAT trial. Neurotherapeutics. 2025;22(2):e00541. doi:10.1016/j.neurot.2025.e00541. PMID:39919936.

Population: Healthy adults aged 23 to 65 years.

Dose protocol: 2 g/day carnosine vs placebo for 12 weeks (n=299)

Key findings: Significant cognitive speed and efficiency improvements in younger adults (23-35 years). Minimal benefit in older participants.

Notes: Large RCT from the NEAT trial. Age-dependent effect is notable. Strongest cognitive signal for carnosine to date.

Paper content

This large RCT from the NEAT trial randomized 299 healthy adults to 2 g/day carnosine or placebo for up to 12 weeks. The study found age-dependent cognitive effects. Younger participants (23-35 years) showed statistically significant improvements in overall cognitive speed and efficiency, with seven individual cognitive tests reaching significance. Older participants showed minimal benefit. The finding suggests carnosine may selectively enhance cognitive performance in younger healthy individuals, possibly reflecting greater capacity for neural optimization in this age group. The study is notable for its relatively large sample size compared to most carnosine cognition trials.

Guides

Setup

Help